Evaluation of Mammaglobin Transcription and its protein in Blood as a Marker For Diagnosis of Breast Cancer | ||||
| Bulletin of Egyptian Society for Physiological Sciences | ||||
| Article 11, Volume 32, Issue 1, June 2012, Page 157-172 PDF (536.88 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/besps.2012.35572 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Hosam El-Ezawy* 1; Rayyh Saleh2; Mona Abd El-Raof3; Enas Abd El-Razik4; Mohamed El Tahmody5; Moones Obada6; Hazem El-Kashef7 | ||||
| 1Department of Clinical Biochemistry, National Liver Institute, Menoufiya University | ||||
| 2Clinical Pathology Department, Faculty of Medicine, Al-Azhar University | ||||
| 3Department of Public Health, National Liver Institute, Menoufiya University | ||||
| 4Department of Oncology , Faculty of Medicine, Menoufiya University | ||||
| 5Department of Pathology, Faculty of Medicine, Menoufiya University | ||||
| 6Departments of Clinical pathology, National Liver Institute, Menoufiya University | ||||
| 7Radiology Department, Faculty of Medicine, Cairo University | ||||
| Abstract | ||||
| Breast cancer is the most common cancer and the second most common cause of cancer death among women in the Western world. As understanding of the pathophysiology of cancer increases, the role of tumor markers becomes more important in the management of cancer patients. An ideal tumor marker should be highly sensitive, specific, and reliable with high prognostic value, organ specific and it should correlate with tumor stages. Human mammaglobin (hMAM) gene was cloned in 1996, hMAM encodes a glycoprotein. The expression of hMAM was initially believed to be restricted to the adult mammary gland and breast cancer cell lines. The aim of the present study was to investigate the clinical reliability of each hMAM mRNA and its transcripts as a tumor marker in breast cancer patients to diagnose breast cancer. The subjects were selected from Oncology Department, Faculty of Medicine Menoufiya University before hormonal, chemotherapy or surgical treatment. Eighty six patients suffering from breast cancer and 59 subjects as a control group were enrolled in this study. The control group was subdivided into 11 apparent healthy subjects (18.6%) and 48 patients served as patient control group (81.4%) suffering from cancers rather than breast cancer. Results: A highly significant increase in the mean serum level of hMAM was detected in the breast cancer patients compared to the control group. Regarding expression of hMAM mRNA, 50 females having breast cancer (73.5%) were positive, while it was negative in 100% of females in the control group. This gave 73.5% sensitivity, 100% specificity, 100% positive predictive value and 76% negative predictive value. Conclusion: The expression of hMAM is restricted to breast epithelial cells. So, hMAM is a promising marker of interest in breast cancer. Further studies are needed to evaluate its usage for screening and staging of breast cancer. | ||||
|
Statistics Article View: 82 PDF Download: 143 |
||||
